In 2023 there were numerous groundbreaking developments in diabetology, metabolic diseases and endocrinology. In the field of diabetes, recommendations for managing cardiovascular diseases (CVDs) in patients with Type 2 diabetes were revised, and a new algorithm for estimating cardiovascular risks in primary prevention was introduced. In addition, patients with diabetes mellitus eligible for a category B convention may claim full reimbursement for a continuous interstitial glucose measurement system using a subcutaneous sensor. The widespread use of glucagon-like peptide-1 (GLP-1) receptor agonists for the therapeutic management of obesity was a notable feature of 2023. In the field of endocrine pathologies, new international guidelines on prolactinoma treatment have been published. Moreover, the 2016 recommendations on the management of adrenal incidentalomas, issued by the European Society of Endocrinology (ESE) in collaboration with the European Network for the Study of Adrenal Tumors (ENSAT), have been updated
Keywords
Diabetes mellitus, cardiovascular risks, continuous glucose monitoring, GLP-1 analogues, obesity, prolactinoma, adrenal incidentaloma